Podcast Douglas W. Blayney, MD @BlayneyDouglas @StanfordMed @BeyondSpringInc #ASCO22 #OncoTwitter @oncoalert  Phase 3 Real-world Effectiveness Of G-CSF In Pts with BC

Podcast Douglas W. Blayney, MD @BlayneyDouglas @StanfordM...

3 月
17 观看
想要稍后再看一次?
登录并添加这个视频到播放列表. 登录
0 0
分类:
描述:

Douglas W. Blayney, MD, FASCO, Clinical researcher and breast oncologist, Professor of Medicine at Stanford University. In this audio, he speaks about the ASCO 2022 Abstract - Real-world effectiveness of prophylactic granulocyte colony-stimulating factor (G-CSF) early (week 1) and late (weeks 2-3) in the cycle for the prevention of febrile neutropenia (FN) among patients (pts) with breast cancer (BC) after high FN–risk chemotherapy (chemo).


Overview:

The major goal of this study is to compare the percentage of patients with DSN =0 in patients treated with:

Docetaxel, doxorubicin, and cyclophosphamide (TAC) plus pegfilgrastim versus TAC + plinabulin/pegfilgrastim combo

Severe neutropenia is defined as an absolute neutrophil count (ANC) of 0.5109/L.

The chemotherapy in this study will consist of docetaxel, doxorubicin, and cyclophosphamide (TAC).